Hisun Pharmaceutical (002099.SZ) released its performance for the first three quarters, with a net loss attributable to shareholders of RMB 136 million.

Zhitong Finance APP News, Haixiang Pharmaceutical (002099.SZ) released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 1.537 billion yuan, a year-on-year increase of 12.44%; net loss attributable to shareholders of the listed company was 136 million yuan; net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses was 183 million yuan; basic earnings per share was -0.09 yuan.